Sodium channel blocker tests allow a clear distinction of electrophysiological characteristics and prognosis in patients with a type 2 or 3 Brugada electrocardiogram pattern
S. Evain(Centre Hospitalier Universitaire de Nantes), Vincent Probst(Centre National de la Recherche Scientifique), François Briec(Centre National de la Recherche Scientifique), Florence Kyndt(Inserm), Gilles Lande(Inserm), Sélim Abbey(Hôpital privé du Confluent), Hervé Le Marec(Centre National de la Recherche Scientifique), Juliette Albuisson(Délégation Paris 5), Jean‐Jacques Schott(Centre National de la Recherche Scientifique)
Cited by 19
Related Papers
HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
|Heart Rhythm|2011|1.5k
Congenital Heart Disease Caused by Mutations in the Transcription Factor <i>NKX2-5</i>
|Science|1998|1.3k
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death
|Nature|2003|961
Long-Term Prognosis of Patients Diagnosed With Brugada Syndrome
|Circulation|2010|850